Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Study Details
Study Description
Brief Summary
The purpose of this study is to characterize the developmental phenotype of ASD and ID and to identify biomarkers using advanced MRI methodology and electrophysiological biomarkers of synaptic function and connectivity predictive of ASD and ID presence and severity in patients with TSC. In addition, this study will be establishing infrastructure for the collection and storage of human bio-specimens, including genetic material, from TSC patients and their family members with ASD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Tuberous Sclerosis Complex (TSC) is a multi-system disease that usually exhibits a high variability in clinical findings both among and within families. About 50% of individuals with TSC develop intellectual disability (ID) and/or autism spectrum disorder (ASD). The purpose of this research study is to learn more information about ASD/ID in individuals with TSC through neurobehavioral assessments, electroencephalogram (EEG) data, and magnetic resonance imaging so that ultimately effective treatments and interventions for ASD/ID can be realized.
Individuals with TSC will be asked to participate in this study if they are 18 months or older at the time of enrollment and have been diagnosed with suspected or confirmed autism spectrum disorder and/or intellectual disability, as well as healthy controls. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals' primary communicative language must be English. The participant and at least one biological parent will be asked to provide biological specimens including DNA and RNA for inclusion in the TSC RDCRN Biorepository.
The study involves 3 on site visits over the course of two years. Study visits will vary in length from about 4 hours to 6 hours. Study visits involve a physical exam, medical history questions, and neuropsychological assessments. A subset of participants between the ages of 2 and 11 years old will take part in the EEG portion of the study. At one point during the study, a blood draw will be done for future research studies. Individuals who have a clinically indicated MRI will have an option to provide routine clinical scans for analysis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Tuberous Sclerosis Complex Tuberous Sclerosis Complex |
Outcome Measures
Primary Outcome Measures
- Change in ADOS-2 scores at end of study [24 months]
Using standardized composite score for ADOS-2 performed yearly to determine ASD
- Change in SBIS-5 scores or Mullen Scales of Early Learning (MSEL) at end of study [24 months]
Using standardized IQ score from the Stanford-Binet Intelligence Scales Fifth Edition (SBIS-5) or Mullen Scales of Early Learning (MSEL) performed yearly to determine ID
- Change in Fractional anisotropy (FA) at 12 months [12 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be fractional anisotropy (FA) determined by MRI diffusion tensor imaging (DTI) with tractography at 12 months radial diffusivity (RD), axial diffusivity (AD), and mean diffusivity (MD) of cerebellar fascicles corresponding to the neuroanatomically-defined excitatory and inhibitory projections cerebellar Purkinje neurons,
- Change in fractional anisotropy (FA) at 24 months [24 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be fractional anisotropy (FA) determined by MRI diffusion tensor imaging (DTI) with tractography at 24 months
- Change in radial diffusivity (RD) at 12 months [12 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be radial diffusivity (RD) determined by MRI diffusion tensor imaging (DTI) with tractography at 12 months
- Change in radial diffusivity (RD) at 24 months [24 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be radial diffusivity (RD) determined by MRI diffusion tensor imaging (DTI) with tractography at 24 months
- Change in mean diffusivity (MD) of cerebellar fascicles at 12 months [12 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be mean diffusivity (MD) of cerebellar fascicles determined by MRI diffusion tensor imaging (DTI) with tractography at 12 months
- Change in mean diffusivity (MD) of cerebellar fascicles at 24 months [24 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be mean diffusivity (MD) of cerebellar fascicles determined by MRI diffusion tensor imaging (DTI) with tractography at 24 months
- Change in axial diffusivity (AD) at 12 months [12 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be axial diffusivity (AD) determined by MRI diffusion tensor imaging (DTI) with tractography at 12 months
- Change in axial diffusivity (AD) at 24 months [24 months]
To determine cerebellum white matter structural integrity, the primary outcome measures will be axial diffusivity (AD) determined by MRI diffusion tensor imaging (DTI) with tractography at 24 months
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meets genetic or clinical diagnostic criteria for TSC (Tuberous Sclerosis), the latter based on current recommendations for diagnostic evaluation, such as physical exam, neuroimaging, and echocardiogram.
-
Age criteria: over 18 months of age at time of enrollment.
-
Is diagnosed or suspected to have ASD and/or ID.
-
Primary communicative language is English
Exclusion Criteria:
-
Has taken an investigational drug as part of another research study, within 30 days prior to study enrollment.
-
For subjects involved in imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator.
-
For subjects involved in EEG/ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or above age 11 at the time of enrollment.
-
Unwilling or unable to comply with study procedures and assessments.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35294 |
| 2 | University of California at Los Angeles | Los Angeles | California | United States | 90095 |
| 3 | Stanford University | Palo Alto | California | United States | 94304 |
| 4 | Boston Children's Hospital | Boston | Massachusetts | United States | 02115 |
| 5 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
| 6 | University of Texas at Houston | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Boston Children's Hospital
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Tuberous Sclerosis Alliance
- National Center for Advancing Translational Science (NCATS)
- Office of Rare Diseases (ORD)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
- Study Chair: Darcy Krueger, MD, PhD, Children's Hospital Medical Center, Cincinnati
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB-P00013585
- 1U54NS092090